08_CD
Development_NOMZ
Ensuring_GER
that_TOBJ
our_FPP1
growing_VBG
range_NN
of_PIN
candidate_NN
drugs_NN
are_VPRT [PASS]
developed_VBN
effectively_RB
to_TO
meet_VB
the_DT
future_JJ
needs_NN
of_PIN
patients_NN
is_VPRT [BEMA]
a_DT
high_JJ
priority_NOMZ
._.
John_NN
Patterson_NN
,_,
Executive_NN
Director_NN
,_,
Development_NOMZ
People_NN
in_PIN
our_FPP1
Development_NOMZ
organization_NOMZ
focus_NN
on_PIN
developing_VBG
better_JJ
drugs_NN
faster_RB
._.
They_TPP3
work_VPRT
globally_RB
in_PIN
therapy_NN
area-led_JJ
product_NN
teams_NN
that_TSUB
bring_VPRT
together_RB
all_QUAN
the_DT
relevant_JJ
functional_JJ
skills_NN
and_PHC
experience_NN
needed_VBN [WZPAST]
for_PIN
the_DT
robust_JJ
,_,
rapid_JJ
progress_NN
of_PIN
new_JJ
medicines_NN
and_CC
the_DT
management_NOMZ
of_PIN
development_NOMZ
risks_NN
._.
We_FPP1
aim_VPRT
to_TO [SPIN]
continuously_RB
improve_VB
the_DT
efficiency_NN
of_PIN
our_FPP1
R&D_NN
by_PIN
simplifying_VBG
our_FPP1
processes_NN
,_,
speeding_VBG
up_RP
decision_NN
making_VBG [WZPRES]
and_PHC
investing_VBG
in_PIN
areas_NN
directly_RB
linked_VBN
to_TO
increasing_VBG
the_DT
quality_NOMZ
and_PHC
number_NN
of_PIN
new_JJ
products_NN
._.
A_DT
new_JJ
clinical_JJ
organisational_JJ
structure_NN
was_VBD [PASS]
announced_VBN [PUBV]
in_PIN
October_NN
2004_CD
to_TO
support_VB
these_DEMO
practices_NN
and_CC
further_JJ
enhance_VB
productivity_NOMZ
._.
In_PIN
January_NN
2005_CD
,_,
we_FPP1
appointed_VBD
an_DT
Executive_NN
Director_NN
for_PIN
Development_NOMZ
a_DT
new_JJ
Board_NN
position_NOMZ
as_IN
part_NN
of_PIN
our_FPP1
accelerated_VBN
significant_JJ
program_NN
of_PIN
change_NN
to_TO
review_VB
our_FPP1
pipeline_NN
and_CC
optimise_VB
the_DT
contribution_NOMZ
of_PIN
our_FPP1
development_NOMZ
and_CC
regulatory_JJ
functions_NOMZ
._.
In_PIN
2004_CD
,_,
18_CD
candidate_NN
drugs_NN
were_VBD [PASS]
selected_VBN
15_CD
in_PIN
2003_CD
and_CC
11_CD
in_PIN
2002_CD
._.
By_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
,_,
there_EX
were_VBD
31_CD
projects_NN
in_PIN
the_DT
preclinical_JJ
phase_NN
and_CC
17_CD
projects_NN
in_PIN
clinical_JJ
phase_NN
1_CD
,_,
17_CD
projects_NN
in_PIN
clinical_JJ
phase_NN
2_CD
and_CC
25_CD
projects_NN
in_PIN
clinical_JJ
phase_NN
3_CD
._.
During_PIN
the_DT
year_NN
we_FPP1
also_RB
concentrated_VBD
on_PIN
progressing_VBG
regulatory_JJ
filings_GER
for_PIN
Exanta_NN
and_CC
supporting_VBG
continued_VBN
launches_NN
of_PIN
new_JJ
products_NN
._.
We_FPP1
also_RB
continue_VPRT
to_TO
look_VB
at_PIN
all_QUAN
the_DT
ways_NN
our_FPP1
existing_VBG
products_NN
can_POMD
be_VB [PASS]
used_VBN
or_CC
improved_VBN
to_TO
get_VB
the_DT
most_EMPH
benefit_VB
for_PIN
patients_NN
and_CC
in_PIN
2004_CD
made_VBD
regulatory_JJ
submissions_NN
for_PIN
new_JJ
uses_NN
for_PIN
Nexium_NN
,_,
Symbicort_NN
and_PHC
Atacand_NN
._.
With_PIN
effect_NN
from_PIN
1_CD
January_NN
2005_CD
thinking_VBG [PRIV]
ahead_PLACE
